France
Delpharm, established in 1988 and headquartered in France, is a leading global figure in the contract development and manufacturing of medicines. With a turnover exceeding 1.1 billion euros and a workforce of over 6,500, the company is a significant player in the Health Care, Manufacturing, and Pharmaceutical industries.
Operating 19 plants across France, Italy, Canada, Poland, and The Netherlands, Delpharm has a broad international footprint. Their strategic expansion approach has involved acquiring production facilities from major pharmaceutical laboratories, leading to its current operation of 18 industrial sites and 3 development centers.
As multispecialists, Delpharm is adept at supplying a vast array of pharmaceutical forms, including tablets, capsules, injectables, and more. Notably, they also offer comprehensive development services, producing clinical batches from phase 1 to phase 3 trials.
The absence of recent investment highlights a potentially self-sustained growth model, making Delpharm a stable prospect for investors seeking exposure to the pharmaceutical supply chain.
